| Name | Bentamapimod |
| Description | Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK. |
| Cell Research | AS 602801 (AS602801) is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate media before use[2]. PANC-1, A2780, and A549 human cancer cells and IMR90 human normal fibroblasts are treated without (control) or with the indicated concentrations of AS 602801 (2.5, 5, and 7.5 μM) for 3 days. The number of viable cells (left panels) and the percentage of dead cells (right panels) are determined using trypan blue as a vital dye[2]. |
| In vitro | Bentamapimod treatment induces cell death and accordingly decreased the number of viable cells in all three cell lines in a dose-dependent manner, suggesting that Bentamapimod may have selective cytotoxic activity against neoplastic cells. Bentamapimod exhibits cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer and glioblastoma at concentrations that did not decrease the viability of normal human fibroblasts. Bentamapimod also inhibits the self-renewal and tumor-initiating capacity of cancer stem cells surviving Bentamapimod treatment[2]. |
| In vivo | Treatment of nude mice bearing xenografts from women with endometriosis (BWE) with 30 mg/kg of AS 602801 (AS602801) resulted in a 29% reduction of lesions. In contrast, neither medroxyprogesterone acetate (MPA) nor progesterone (PR) alone led to regression of BWE lesions. However, a combination of 10 mg/kg AS 602801 with MPA achieved a 38% lesion regression. When applied to human endometrial organ cultures (from healthy women), AS 602801 or MPA decreased the release of matrix metalloproteinase-3 (MMP-3) into the culture medium. In BWE-established organ cultures, PR or MPA did not affect MMP-3 secretion, whereas AS 602801, either alone or in combination with MPA, effectively suppressed MMP-3 production. In an autologous rat endometriosis model, AS 602801 facilitated a 48% reduction in lesions, compared to an 84% reduction with the GnRH antagonist Antide. Additionally, AS 602801 diminished inflammatory cytokine levels in endometriotic lesions without altering cytokine levels in the ipsilateral horns. It also enhanced natural killer cell activity with no observed adverse effects on the uterus[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 2.5 mg/mL (5.46 mM), Suspension.
DMSO : 4.58 mg/mL (10.01 mM), Sonication is recommended.
|
| Keywords | JNK3 | JNK2 | JNK1 | JNK | Inhibitor | inhibit | Bentamapimod | AS-602801 | AS602801 |
| Inhibitors Related | Astragaloside IV | Teneligliptin hydrobromide | Berberine hydrogen sulphate | SP600125 | Chloranil | (-)-Bornyl acetate | Benzbromarone | Anisomycin | Chloramphenicol | Metacetamol | Berberine sulfate | Benzyl salicylate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
